| 16.6 -0.13 (-0.78%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.19 | 1-year : | 25.92 |
| Resists | First : | 19 | Second : | 22.19 |
| Pivot price | 16.14  |
|||
| Supports | First : | 14.82 | Second : | 12.24 |
| MAs | MA(5) : | 16.43 |
MA(20) : | 15.29 |
| MA(100) : | 13.96 |
MA(250) : | 12.93 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 61.8 |
D(3) : | 61.2 |
| RSI | RSI(14): 58.2 |
|||
| 52-week | High : | 20.5 | Low : | 7.98 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GHRS ] has closed below upper band by 38.0%. Bollinger Bands are 35.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.94 - 17.05 | 17.05 - 17.15 |
| Low: | 15.77 - 15.88 | 15.88 - 15.97 |
| Close: | 16.44 - 16.62 | 16.62 - 16.77 |
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Mon, 26 Jan 2026
GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Sat, 24 Jan 2026
GHRS: RBC Capital Raises Price Target to $40, Maintains 'Outperf - GuruFocus
Fri, 23 Jan 2026
GH Research stock price target raised to $40 from $33 at RBC Capital - Investing.com
Thu, 22 Jan 2026
GH Research to Present at RBC Capital Markets Psychedelics Symposium - TipRanks
Fri, 16 Jan 2026
GH Research (GHRS) Is Up 9.1% After FDA Lifts Clinical Hold On GH001 Depression Drug - Sahm
Mon, 12 Jan 2026
How FDA’s Lifted Clinical Hold On GH001 At GH Research (GHRS) Has Changed Its Investment Story - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 26.7 (%) |
| Held by Institutions | 71.9 (%) |
| Shares Short | 2,310 (K) |
| Shares Short P.Month | 2,030 (K) |
| EPS | -0.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -14.2 % |
| Return on Equity (ttm) | -17.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -42 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -22.74 |
| PEG Ratio | 0 |
| Price to Book value | 3.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -24.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|